trending Market Intelligence /marketintelligence/en/news-insights/trending/HcR3ogCExrtFzJJ6OgSNqg2 content esgSubNav
In This List

TheraNexus to raise €18M via IPO to fund R&D, expansion

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


TheraNexus to raise €18M via IPO to fund R&D, expansion

TheraNexus said it intends to raise €18 million via an initial public offering on the Euronext Exchange to further develop its clinical pipeline and invest in its biotechnology research and development.

Founded in Lyon in 2013 by two former researchers at France's alternative energies and atomic energy commission, TheraNexus specializes in neurological disorders including Parkinson's disease, Alzheimer's and neuropathic pain.

The shares have been priced at an indicative range of €14 euro to €18.80. TheraNexus said existing shareholders and new investors have subscribed to shares worth up to €10.9 million thus far.

After a six-month absence in healthcare IPOs on the Euronext Exchange, TheraNexus is the second company in the healthcare sector this week to announce listing plans.